Teva wins reversal of $235m GSK patent verdict -report

A federal judge on Wednesday overturned a jury’s verdict that required Teva Pharmaceutical Industries to pay GlaxoSmithKline more than $235 million for infringing a patent covering its blood pressure drug Coreg, according to a Reuters report.

US District Judge Leonard Stark in Wilmington, Delaware, ruled that the evidence did not support the jury’s finding in June that Teva sales of a generic version of the drug caused doctors to infringe GSK’s patent.

The jury had awarded GSK $234.1 million in lost profits and said the drug company deserved an additional $1.4 million in royalties. It also had rejected Teva’s contention that the patent was invalid, a decision Stark did not overturn.

“We are disappointed with the judge’s decision and are reviewing our options,” GSK said in a statement.

Teva declined to comment.

The case is GlaxoSmithKline LLC et al v. Teva Pharmaceuticals USA Inc, U.S. District Court, District of Delaware, No. 14-cv-00878.